Effective management of coronary heart disease (CHD) is essential, particularly for patients with comorbidities like diabetes, chronic kidney disease, or heart failure. Latest studies have proven that personalized treatment based on age, risk factors, and cholesterol levels improves patient outcomes. Guidelines prioritize this tailored approach, recommending interventions that address both cardiovascular and comorbid conditions. Comprehensive analysis and detailed guidelines are available online for further reference.

Patients with type 2 diabetes mellitus (T2DM) and elevated cardiovascular (CV) risk benefit from interventions that significantly reduce major CV events, myocardial infarctions, and strokes. Clinical trials such as CARDS Trial highlight reductions of up to 37% in major CV events and up to 48% in stroke risk, with effective lowering of LDL-C to target levels. Current clinical guidelines recommend targeted approaches to minimize cardiovascular complications in diabetes and chronic kidney disease (CKD) patients.

Intensive lipid-lowering therapy is proven to reduce the risk of recurrent stroke, heart attacks, and other vascular events in patients with a history of ischemic stroke or transient ischemic attack (TIA). This therapy significantly lowers both fatal and nonfatal strokes, as well as coronary and peripheral events when compared with placebo, based on SPARCL Trial. Prioritizing lipid management is essential for poststroke prevention and long-term cardiovascular protection.